A review of genetic epidemiology of head and neck cancer related to polymorphisms in metabolic genes, cell cycle control and alcohol metabolism;Revisione narrativa sulla epidemiologia genetica dei polimorfismi, dei geni metabolici, dei geni del ciclo cellulare e dei geni del metabolismo dell'alcool, implicati nel rischio del cancro testa-collo

Acta Otorhinolaryngologica Italica

Volumn 32, Issue 1, 2012, Pages 1-11

  Cadoni, G ^a   Boccia, S ^a,b   Petrelli, L ^a   Di Giannantonio, P ^a   Arzani, D ^a   Giorgio, A ^a   De Feo, E ^a   Pandolfini, M ^a   Galli P ^a   Paludetti, G ^a   Ricciardi, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

Author keywords

Genetic polymorphisms; Genetic susceptibility; Head and neck cancer

Indexed keywords

ALCOHOL;

CELL CYCLE CHECKPOINT; GENETIC POLYMORPHISM; GENETICS; HEAD AND NECK TUMOR; HUMAN; METABOLISM; MOLECULAR EPIDEMIOLOGY; REVIEW;

CELL CYCLE CHECKPOINTS; ETHANOL; HEAD AND NECK NEOPLASMS; HUMANS; METABOLISM; MOLECULAR EPIDEMIOLOGY; POLYMORPHISM, GENETIC;

EID: 84861797305     PISSN: 0392100X     EISSN: 1827675X     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Szymańska K, Levi JE, Menezes A, et al. TP53 and EGFR mutations in combination with lifestyle risk factors in tu-mours of the upper aerodigestive tract from South America. Carcinogenesis 2010;31:1054-1059.
2. Hiyama T, Yoshihara M, Tanaka S, et al. Genetic polymor-phisms and head and neck cancer risk (Review). Int J Oncol 2008;32:945-73.
3. Hashibe M, Brennan P, Benhamou S, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drink-ers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;16;99:777-89.
4. Marron M, Boffetta P, Zhang ZF, et al. Cessation of alcohol drinking, tobacco smoking and the reversal of head and neck cancer risk. Int J Epidemiol 2010;39:182-96.
5. Chuang SC, Jenab M, Heck JE, et al. Diet and the risk of head and neck cancer: a pooled analysis in the INHANCE consortium. Cancer Causes Control 2012;23:69-88.
6. Stott-Miller M, Chen C, Chuang SC, et al. History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2012;21:294-304.
7. Nicolotti N, Chuang SC, Cadoni G, et al. Recreational physical activity and risk of head and neck cancer: a pooled analysis within the international head and neck cancer epidemiology (INHANCE) Consortium. Eur J Epidemiol 2011;26:619-628.
8. De Feo E, Rowell J, Cadoni G, et al. A case-control study on the effect of apoliprotein E genotype on head and neck cancer risk. Cancer Epidemiol Biomarkers Prev 2010;19:2839-2846.
9. Negri E, Boffetta P, Berthiller J, et al. Family history of cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Int J Cancer 2009;124:394-401.
10. McKay JD, Truong T, Gaborieau V, et al. A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet 2011;7:e1001333.
11. Gianfagna F, De Feo E, van Duijn CM, et al. A systematic review of meta-analyses on gene polymorphisms and gastric cancer risk. Curr Genomics 2008;9:361-374.
12. Matthias C, Bockmuhl U, Jahnke V, et al. Polymorphism in cytochrome P450 CYP2D6, CYP1A1, CYP2E1 and glutathione S-transferase, GSTM1, GSTM3, GSTT1 and susceptibility to tobacco-related cancers: studies in upper aerodigestive tract cancers. Pharmacogenetics 1998;8:91-100.
13. Katoh T, Kaneko S, Kohshi K, et al. Genetic polymorphisms of tobacco-and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 1999;83:606-9.
14. Morita S, Yano M, Tsujinaka T, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 1999;80:685-688.
15. Marques CFS, Koifman S, Koifman RJ, et al. Influence of CYP1A1, CYP2E1, GSTM3, and NAT2 genetic polymor-phisms in oral cancer susceptibity: results from a case-control study in Rio de Janeiro. Oral Oncol 2006;42:632-637.
16. Sugimura T, Kumimoto H, Tohnai I, et al. Gene-environment interaction involved in oral carcinogenesis: molecular epi-demiological study for metabolic and DNA repair gene poly-morphisms. J Oral Pathol Med 2006;35:11-18.
17. Gattas GJF, De Carvalho MB, Siraque MS, et al. F, CYP2E1, GSTM1, and GSTT1 associated with head and neck cancer. Head Neck 2006;28:819-826.
18. Hung HC, Chuang J, Chien YC, et al. Genetic polymorphisms of CYP2E1, GSTM1, and GSTT1; environmental factors and risk of oral cancer. Cancer Epidemiol Biomarkers Prev 1997;6:901-905.
19. Bouchardy C, Hirvonen A, Coutelle C, et al. Role of alcohol dehydrogenase 3 and cytochrome P-4502E1 genotypes in susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 2000;87:734-740.
20. Neuhaus T, Ko YD, Lorenzen K, et al. Association of cyto-chrome P450 2E1 polymorphisms and head and neck squa-mous cell cancer. Toxicol Lett 2004;151:273-282.
21. Hildesheim A, Chen CJ, Caporaso NE, et al. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Cancer Epidemiol Biomarkers Prev 1995;4:607-10.
22. Hildesheim A, Anderson LM, Chen CJ, et al. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 1997;89:1207-1212.
23. Gonzalez MV, Alvarez V, Pello MF, et al. Genetic polymor-phism of N-acetyltransferase-2, glutathione S-transferase-M1, and cytochromes P450IIE1 and P450IID6 in the susceptibility to head and neck cancer. J Clin Pathol 1998;51:294-298.
24. Kongruttanachok N, Sukdikul S, Setavarin S, et al. Cyto-chrome P450 2E1 polymorphism and nasopharyngeal car-cinoma development in Thailand: a correlative study. BMC Cancer 2001;1:4.
25. Gajecka M, Rydzanicz M, Jaskula-Sztul R, et al. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the in-creased risk of the laryngeal squamous cell carcinoma. Mu-tat Res 2005;574:112-123.
26. Zhuo WL, Wang Y, Zhuo XL, et al. Polymorphisms of CYP1A1 and GSTM1 and laryngeal cancer risk: evidence-based me-ta-analyses. J Cancer Res Clin Oncol 2009;135:1081-90.
27. Park JY, Muscat JE, Ren Q, et al. CYP1A1 and GSTM1 polymorphisms and oral cancer risk. Cancer Epidemiol Biomar-kers Prev 1997;6:791-797.
28. Sato M, Sato T, Izumo T et al. Genetically high susceptibity to oral squamous cell carcinoma in terms of combined genotyping of CYP1A1 and GSTM1 genes. Oral Oncol 2000;36:267-271.
29. Sreelekha TT, Ramadas K, Pandey M, et al. Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes in Indian oral cancer. Oral Oncol 2001;37:593-598.
30. Varzim G, Monteiro E, Silva RA, et al. CYP1A1 and XRCC1 gene polymorphisms in SCC of the larynx. Eur J Cancer Prev 2003;12:495-499.
31. Ruwali M, Parmar D. Association of functionally im-portant polymorphisms in cytochrome P450s with squa-mous cell carcinoma of head and neck. Indian J Exp Biol 2010;48:651-665.
32. Boccia S, Cadoni G, Sayed-Tabatabaei FA, et al. CYP1A1,CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. J Cancer Res Clin Oncol 2008;134:93-100.
33. Varela-Lema L, Taioli E, Ruano-Ravina A, et al. Meta-anal-ysis and pooled analysis of GSTM1 and CYP1A1 polymorphisms and oral and pharyngeal cancers: a HuGE-GSEC review. Genet Med 2008;10:369-384.
34. Zhang ZJ, Hao K, Shi R, et al. Glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: a HuGE review and meta-analysis. Am J Epidemiol 2011;173:847-857.
35. Sato M, Sato T, Izumo T, et al. Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer. Carcinogenesis 1999;20:1927-1931.
36. Trizna Z, Clayman GL, Spitz MR, et al. Glutathione S-trans-ferase genotypes as risk factors for head and neck cancer. Am J Surg 1995;170:499-501.
37. Coutelle C, Ward PJ, Fleury B, et al. Laryngeal and oropharyn-geal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. Hum Genet 1997;99:319-325.
38. Lafuente A, Maristany M, Arias C, et al. Glutathione and glutathione S-transferase in human squamous cell carcino-mas of the larynx and GSTM1 dependent risk. Anticancer Res 1998;18:107-111.
39. Cheng L, Sturgis EM, Eicher SA, et al. Glutathione-S-trans-ferase polymorphisms and risk of squamous-cell carcinoma of the head and neck. Int J Cancer 1999:84:220-224.
40. Nomura T, Noma H, Shibahara T, et al. Aldehyde dehydroge-nase 2 and glutathione S-transferase M1 polymorphisms in relation to the risk for oral cancer in Japanese drinkers. Oral Oncol 2000;36:42-46.
41. Park JY, Muscat JE, Kaur T, et al. Comparison of GSTM pol-ymorphisms and risk for oral cancer between African-Americans and Caucasians. Pharmacogenetics 2000;10:123-131.
42. Hong YJ, Lee JK, Lee GH, et al. Influence of glutathione S-transferase M1 and T1 genotypes on larynx cancer risk among Korean smokers. Clin Chem Lab Med 2000;38:917-919.
43. Kietthubthew S, Sriplung H, Au WW. Genetic and environmental interactions on oral cancer in Southern Thailand. Environ Mol Mutagen 2001;37:111-116.
44. Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 2002;23:803-807.
45. Bardakci F, Canbay E, Degerli N, et al. Relationship of to-bacco smoking with GSTM1 gene polymorphism in laryngeal cancer. J Cell Mol Med 2003;7:307-12.
46. Drummond SN, De Marco L, Noronha JCM, et al. GSTM1 polymorphism and oral squamous cell carcinoma. Oral On-col 2004;40:52-55.
47. Peters ES, McClean MD, Marsit CJ, et al. Glutathione S-transferase polymorphisms and the synergy of alcohol and tobacco in oral, pharyngeal, and laryngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:2196-2202.
48. Acar H, Ozturk K, Muslumanoglu MH, et al. Relation of glutathione S-transferase genotypes (GSTM1 and GSTT1) to laryngeal squamous cell carcinoma risk. Cancer Genet Cy-togenet 2006;169:89-93.
49. Capoluongo E, Almadori G, Concolino P, et al. GSTT1 and GSTM1 allelic polymorphisms in head and neck cancer patients from Italian Lazio region. Clin Chem Acta 2007;376:174-178.
50. Hashibe M, Brennan P, Strange RC, et al. Meta-and pooled analyses of GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes and risk of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2003;12:1509-17.
51. Tripathy CB, Roy N. Meta-analysis of glutathione S-trans-ferase M1 genotype and risk toward head and neck cancer. Head Neck 2006;28:217-224.
52. Jahnke V, Matthias C, Fryer A, et al. Glutathione S-trans-ferase and cytochrome-P450 polymorphism as risk fac-tors for squamous cell carcinoma of the larynx. Am J Surg 1996;172:671-673.
53. Sharma A, Mishra A, Das BC, et al. Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer. Neoplasma 2006;53:309-315.
54. Hamel N, Karimi S, Hebert-Blouin MN, et al. Increased risk of head and neck cancer in association with GSTT1 nul-lizygosity for individuals with low exposure to tobacco. Int J Cancer 2000;87:452-454.
55. Drummond SN, Gomez RS, Noronha JCM, et al. Association between GSTT-1 gene deletion and the susceptibility to oral squamous cell carcinoma in cigarette-smoking subjects. Oral Oncol 2005;41:515-519.
56. Sikdar N, Paul RR, Roy B. Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer 2004;109:95-101.
57. Matthias C, Bockmuhl U, Jahnke V, et al. The glutathione S-transferase GSTP1 polymorphism: effects on susceptibility to oral/pharyngeal and laryngeal carcinomas. Pharmacoge-netics 1998;8:1-6.
58. Park JY, Schantz SP, Stern JC, et al. Association between glutathione S-transferase π genetic polymorphisms and oral cancer risk. Pharmacogenetics 1999;9:497-504.
59. Katoh T, Kaneko S, Takasawa S, et al. Human glutathione S-transferase P1 polymorphism and susceptibility to smoking related epithelial cancer; oral, lung, gastric, colorectal and urothelial cancer. Pharmacogenetics 1999;9:165-169.
60. Olshan AF, Weissler MC, Watson MA, et al. GSTM1, GSTT1, GSTP1, CYP1A1, and NAT1 polymorphisms, tobacco use, and the risk of head and neck cancer. Cancer Epidemiol Bi-omarkers Prev 2000;9:185-191.
61. McWilliams JE, Evans AJ, Beer TM, et al. Genetic poly-morphisms in head and neck cancer risk. Head Neck 2000;22:609-617.
62. Evans AJ, Henner WD, Eilers KM, et al. Polymorphisms of GSTT1 and related genes in head and neck cancer risk. Head Neck 2004;26:63-70.
63. Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of P53 in tumor tissue. Cancer Res 2001;61:4398-4404.
64. Cheng YJ, Chien YC, Hildesheim A, et al. No association between genetic polymorphisms of CYP1A1, GSTM1, GSTT1, GSTP1, NAT2, and nasopharyngeal carcinoma in Taiwan. Cancer Epidemiol Biomarkers Prev 2003;12:179-180.
65. Jourenkova-Mironova N, Voho A, Bouchardy C, et al. Glutathione S-transferase GSTM1, GSTM3, GSTP1 and GSTT1 genotypes and the risk of smoking-related oral and pharyn-geal cancers. Int J Cancer 1999;81:44-48.
66. Cabelguenne A, Loriot MA, Stucker I, et al. Glutathione associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. Int J Cancer 2001;93:725-30.
67. To-Figueras J, Gene M, Gomez-Catalan J, et al. Microsomal epoxide hydrolase and glutathione S-transferase polymorphisms in relation to laryngeal carcinoma risk. Cancer Lett 2001;87:95-101.
68. Majumder M, Sikdar N, Paul RR, et al. Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among smokers carrying two risk genotypes: one of each of two loci, GSTM3 and XRCC1 (codon 280). Cancer Epidemiol Biomarkers Prev 2005;14:2106-2112.
69. Oude O.M, Manni JJ, Peters WHM. Glutathione S-transferase T1 null polymorphism and the risk for head and neck cancer. Acta Otolaryngol 2006;126:311-317.
70. Jourenkova-Minorova N, Voho A, Bouchardy C, et al. Glu-tathione S-transferase GSTM3 and GSTP1 genotypes and larynx cancer risk. Cancer Epidemiol Biomarkers Prev 1999;8:185-188.
71. Kelders WPA, Oude O.MB, Roelofs HMJ, et al. The association between glutathione S-transferase P1 genotype and plasma level in head and neck. Laryngoscope 2002;112:462-466.
72. Amador AG, Righi PD, Radpour S, et al. Polymorphisms of xenobiotic metabolizing genes in oropharyngeal carci-noma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:440-445.
73. Oude O.MB, Roelofs HNJ, van den Brandt PA, et al. Polymorphisms of the glutathione S-transferase P1 gene and head and neck cancer susceptibility. Head Neck 2003;25:37-43.
74. Cho CG, Lee SK, Nam SY, et al. Association of the GSTP1 and NQO1 polymorphisms and head and neck squamous cell carcinoma risk. J Korean Med Sci 2006;21:1075-1059.
75. Agúndez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab 2008;9:520-531.
76. Hahn M, Hagedorn G, Kuhlisch E, et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to oral cavity cancer. Oral Oncol 2002;38:486-490.
77. Katoh T, Kaneko S, Boissy R, et al. A pilot study testing the association between N-acetyltransferases 1 and 2 and risk of oral squamous cell carcinoma in Japanese people. Carcino-genesis 1998;19:1803-1807.
78. Varzim G, Monteiro E, Siva R, et al. Polymorphisms of ar-ylamine N-acetyltransferase (NAT1 and NAT2) and larynx cancer susceptibility. ORL 2002;64:206-212.
79. Chen C, Ricks S, Doody DR, et al. N-acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consump-tion, and oral squamous cell cancer risk. Carcinogenesis 2001;22:1993-2019.
80. Ying XJ, Dong P, Shen B, et al. Possible association of NAT2 polymorphism with laryngeal cancer risk: an evidence-based meta-analysis. J Cancer Res Clin Oncol 2011;137:1661-1667.
81. Buch SC, Nazar-Stewart V, Weissfeld JL, et al. Case-con-trol study of oral and oropharyngeal cancer in whites and genetic variation in eight metabolic enzymes. Head Neck 2008;30:1139-1147.
82. Demokan S, Suoglu Y, Gözeler M, et al. N-acetyltransferase 1 and 2 gene sequence variants and risk of head and neck cancer. Mol Biol Rep 2010;37:3217-3226.
83. Li X, Hu Z, Qu X, et al. Putative EPHX1 enzyme activity is re-lated with risk of lung and upper aerodigestive tract cancers: a comprehensive meta-analysis. PLoS One 2011;6:e14749.
84. Yokoyama A, Muramatsu T, Ohmori T, et al. Alcohol-related cancers and aldehyde dehydrogenase-2 in Japanese alcoholics. Carcinogenesis 1998;19:1383-1387.
85. Yokoyama A, Muramatsu T, Ohmori T, et al. Alcohol and al-dehyde dehydrogenase gene polymorphisms and oropharyn-golaryngeal, esophageal and stomach cancers in Japanese alcoholics. Carcinogenesis 2001;22:433-439.
86. Asakage T, Yokoyama A, Haneda T, et al. Genetic polymor-phisms of alcohol and aldehyde dehydrogenases, and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell carcinoma. Carcinogenesis 2007;28:865-874.
87. Tiemersma EW, Wark PA, Ocke MC, et al. Alcohol consumption, alcohol dehydrogenase 3 polymorphism, and colorectal ad-enomas. Cancer Epidemiol Biomarkers Prev 2003;12:419-425.
88. Harty LC, Caporaso NE, Hayes RB, et al. Alcohol dehydro-genase 3 genotype and risk of oral cavity and pharyngeal cancers. J Natl Cancer Inst 1997;89:1968-1975.
89. Olshan AF, Weissler MC, Watson MA, et al. Risk of head and neck cancer and the alcohol dehydrogenase 3 genotype. Carcinogenesis 2001;22:57-61.
90. Sturgis EM, Dahlstrom KR, Guan Y, et al. Alcohol dehydro-genase 3 genotype is not associated with risk of squamous cell carcinoma of the oral cavity and pharynx. Cancer Epide-miol Biomarkers Prev 2001;10:273-275.
91. Schwarts SM, Doody DR, Fitzgibbons ED, et al. Oral sq-uamous cell cancer risk in relation to alcohol consumption and alcohol dehydrogenase-3 genotypes. Cancer Epidemiol Biomarkers Prev 2001;10:1137-1144.
92. Zavras AI, Wu T, Laskaris G, et al. Interaction between a sin-gle nucleotide polymorphism in the alcohol dehydrogenase 3 gene, alcohol consumption and oral cancer risk. Int J Cancer 2002;97:526-530.
93. Nishimoto IN, Pinheiro NA, Rogatto SR, et al. Alcohol dehydrogenase 3 genotype as a risk factor for upper aero-digestive tract cancers. Arch Otolaryngol Head Neck Surg 2004;130:78-82.
94. González CA, Sala N, Capellá G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002;100:249-260.
95. Drapkin R, Sancar A, Reinberg D. Where transcription meets repair. Cell 1994;77:9-12.
96. Qiao Y, Spitz MR, Shen H, et al. Modulation of repair of ul-traviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes. Carcinogenesis 2002;23:295-299.
97. Kietthubthew S, Sriplung H, Au WW, et al. Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand. Int J Hyg Environ Health 2006;209:21-9.
98. Majumder M, Sikdar N, Ghosh S, et al. Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Int J Cancer 2007;120:2148-2156.
99. Gajecka M, Rydzanicz M, Jaskula-Sztul R, et al. Reduced DNA repair capacity in laryngeal cancer subjects. Adv Otorhinolaryngol 2005;62:25-37.
100. Sturgis EM, Zheng R, Li L, et al. XPD/ERCC2 polymor-phisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis 2000;21:2219-2223.
101. Ramachandran S, Ramadas K, Hariharan R, et al. Single nu-cleotide polymorphisms of DNA repair genes XRCC1 and XPD and its molecular mapping in Indian oral cancer. Oral Oncol 2006;42:350-362.
102. Huang WY, Olshan AF, Schwarts SM, et al. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epi-demiol Biomarkers Prev 2005;14:1747-1753.
103. Pabalan N, Bapat B, Sung L, et al. Cyclin D1 Pro241Pro (CCND1-G870A) polymorphism is associated with increased cancer risk in human populations: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2008;17:2773-2781.
104. Papadimitrakopoulou V, Izzo JG, Liu DD, et al. Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) 2009;2:14-21.
105. Deng L, Zhao XR, Pan KF, et al. Cyclin D1 polymorphism and susceptibility to NPC using DHPLC. Acta Biochem Bio phys Sinica 2002;34:16-20.
106. Wong YK, Lin SC, Chang CS, et al. Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 2003;32:265-270.
107. Nishimoto IN, Pinheiro NA, Rogatto SR, et al. Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive system in non-alcoholics. Oral Oncol 2004;40:604-610.
108. Monteiro E, Varzim G, Pires AM, et al. Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cellcarcinoma: implications of tumor localization and tobacco exposure. Cancer Detect Prev 2004;28:237-243.
109. Holley SL, Matthias C, Jahnke V, et al. Association of cyclin D1 polymorphism with increased susceptibility to oral squa-mous cell carcinoma. Oral Oncol 2005;41:156-60.
110. Catarino RJ, Breda E, Coelho V, et al. Association of the A870G yclin D1 gene polymorphism with genetic susceptibility to na-sopharyngeal carcinoma. Head Neck 2006;28:603-608.
111. Zheng Y, Shen H, Sturgis EM, et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis 2001;22:1195-1199.
112. Rydzanicz M, Golusinski P, Mielcarek-Kuchta D, et al. Cyclin-D1 gene (CCND1) polymorphism and the risk of squa-mous cell carcinoma of the larynx. Eur Arch Otorhinolaryn-gol 2006;263:43-48.
113. Sathyan KM, Nalinakumari KR, Abraham T, et al. Influence of single nucleotide polymorphisms in H-Ras and cyclin D1 genes on oral cancer susceptibility. Oral Oncol 2006;42:607-613.
114. Tsai MH, Tsai CW, Tsou YA, et al. Significant association of cyclin D1 single nucleotide polymorphisms with oral cancer in taiwan. Anticancer Res 2011;31:227-231.
115. Golusinski P, Lamperska K, Pazdrowski J, et al. Analysis of mutations within the TP53 gene in patients with squa-mous cell carcinoma of the head and neck. Otolaryngol Pol 2011;65:114-121.
116. Gallì P, Cadoni G, Volante M, et al. A case-control study on the combined effects of P53 and P73 polymorphisms on head and neck cancer risk in an Italian population. BMC Cancer 2009;9:137.
117. Thomas M, Kalita A, Labrecque S, et al. Two polymorphic variants of wild-type P53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-1100.
118. Lu J, Wang LE, Xiong P, et al. 172G>T variant in the 5' un-translated region of DNA repair gene RAD51 reduces risk of squamous cell carcinoma of the head and neck and interacts with a P53 codon 72 variant. Carcinogenesis 2007;28:988-994.
119. Birgander R, Sjalander A, Zhou Z, et al. P53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered 1996;46:49-54.
120. Golovleva I, Birgander R, Sjalander A, et al. Interferon-α and P53 alleles involved in nasopharyngeal carcinoma. Car-cinogenesis 1997;18:645-649.
121. Hamel N, Black MJ, Ghadirian P, et al. No association between P53 codon 72 polymorphism and risk of squamous cell carcinoma of the head and neck. Br J Cancer 2000;82:757-759.
122. Summersgill KF, Smith EM, Kirchner HL, et al. P53 polymorphism, human papillomavirus infection in the oral cavity, and oral cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:334-349.
123. Tandle AT, Sanghvi V, Saranath D. Determination of P53 genotypes in oral cancer patients from India. Br J Cancer 2001;84:739-742.
124. Shen H, Zheng Y, Sturgis EM, et al. P53 codon 72 polymor-phism and risk of squamous cell carcinoma of the head and neck: a case-control study. Cancer Lett 2002;183:123-30.
125. Drummond SN, De Marco L, Pordeus IDA, et al. TP53 codon 72 polymorphism in oral squamouos cell carcinoma. Anticancer Res 2002;22:3379-3381.
126. Tiwawech D, Srivantanakul P, Karaluk A, et al. The P53 co-don 72 polymorphism in Thai nasopharyngeal carcinoma. Cancer Lett 2003;198:69-75.
127. Kietthubthew S, Sriplung H, Au WW, et al. The P53 codon 72 polymorphism and risk of oral cancer in Southern Thailand. Asian Pac J Cancer Prev 2003;4:209-214.
128. Katiyar S, Thelma BK, Murthy NS, et al. Polymorphism of the P53 codon 72 arg/pro and the risk of HPV type 16/18-as-sociated cervical and oral cancer in India. Mol Cell Bio-chem 2003;252:117-124.
129. Cortezzi SS, Provazzi PJ, Sobrinho JS, et al. Analysis of hu-man papillomavirus prevalence and TP53 polymorphism in head and neck squamous cell carcinomas. Cancer Genet Cy-togenet 2004;150:44-9.
130. Twu CW, Jiang RS, Shu CH, et al. Association of P53 codon 72 polymorphism with risk of hypopharyngeal sq-uamous cell carcinoma in Taiwan. J Formos Med Assoc 2006;105:99-104.
131. Sousa H, Santos AM, Catarino R, et al. Linkage of TP53 codon 72 pro/pro genotype as predictive factor for nasopharyngeal carcinoma development. Eur J Cancer Prev 2006;15:362-366.
132. Yung WCW, Ng MH, Sham JST, et al. P53 codon 72 polymorphism in nasopharyngeal carcinoma. Cancer Genet Cy-togenet 1997;93:181-182.
133. Sourvinos G, Rizos E, Spandidos DA. P53 codon 72 poly-morphism is linked to the development and not the progression of benign and malignant laryngeal tumours. Oral Oncol 2001;37:572-578.
134. Scheckenback K, Lieven O, Gotte K, et al. P53 codon 72 polymorphic variants, loss of allele-specific transcription, andhuman papilloma virus 16 and/or 18 E6 messenger RNA ex-pression in squamous cell carcinomas of the head and neck. Cancer Epidemiol Biomarkers Prev 2004;13:1805-1809.
135. Perrone F, Mariani L, Pastore E, et al. P53 codon 72 polymorphisms in human papillomavirus-negative and papillomavi-rus-positive squamous cell carcinomas of the oropharynx. Cancer 2007;109:2461-2465.
136. Zhuo XL, Li Q, Zhou Y, et al. Study on TP53 codon 72 poly-morphisms with oral carcinoma susceptibility. Arch Med Res 2009;40:625-634.
137. Zhuo XL, Cai L, Xiang ZL, et al. TP53 codon 72 polymor-phism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res 2009;40:299-305.
138. Bradford CR, Zhu S, Ogawa H, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck 2003;25:654-661.
139. Poeta ML, Manola J, Goldwasser MA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 2007;357:2552-2561.
140. Worsham MJ, Chen KM, Meduri V, et al. Epigenetic events of disease progression in head and neck squamous cell carci-noma. Arch Otolaryngol Head Neck Surg 2006;132:668-677.
141. Ferru A, Denis S, Guilhot J, et al. Expression of TAP73 and DeltaNP73 isoform transcripts in thyroid tumours. Eur J Surg Oncol 2006;32:228-230.
142. Chen YK, Hsue SS, Lin LM. P73 expression for human buc-cal epithelial dysplasia and squamous cell carcinoma: does it correlate with nodal status of carcinoma and is there a relationship with malignant change of epithelial dysplasia? Head Neck 2004;26:945-952.
143. Boccia S, Cadoni G, La Torre G, et al. A case-control study investigating the role of sulfotransferase 1A1 polymorphism in head and neck cancer. J Cancer Res Clin Oncol 2006;132:466-472.
144. Macgregor S, Lind PA, Bucholz KK, et al. Associations of ADH and ALDH2 gene variation with self report alcohol reactions consumption and dependence: an integrated analysis. Hum Mol Genet 2009;18:580-593.
145. Tolstrup JS, Nordestgaard BG, Rasmussen S, et al. Alcohol-ism and alcohol drinking habits predicted from alcohol dehy-drogenase genes. Pharmacogenomics J 2008;8:220-227.
146. Zuccolo L, Fitz-Simon N, Gray R, et al. A non-synonymous variant in ADH1B is strongly associated with prenatal alco-hol use in a European sample of pregnant women. Hum Mol Genet 2009;15:4457-4466.
147. Luo X, Kranzler HR, Zuo L, et al. Diplotype trend regression analysis of the ADH gene cluster and the ALDH2 gene: multiple significant associations with alcohol dependence. Am J Hum Genet 2006;78:973-987.
148. Ricciardi W, Boccia S. Assessment of genomics as a priority for Public Health. Eurohealth 2007;13:7-9.
149. Hu Z, Ma H, Chen F, et al. XRCC1 polymorphisms and can-cer risk: a meta-analysis of 38 case-control studies. Cancer Epidemiol Biomarkers Prev 2005;14:1810-1818.